Showing results (1171-1180 of 1,358) with videos related to
Sort By:
Pageof 136
Clinical Journal of the American Society of Nephrology : CJASN|March 4, 2021
Proteinuria and Clinical Outcomes in Hospitalized COVID-19 Patients: A Retrospective Single-Center StudyAlexandre Karras, Marine Livrozet, Hélène Lazareth, et al.Blood Advances|November 9, 2022
The promising efficacy of a risk-based letermovir use strategy in CMV-positive allogeneic hematopoietic cell recipientsMathilde Sourisseau, Emmanuel Faure, Hélène Béhal, et al.BMC Nephrology|January 10, 2018
Uncontrolled donation after circulatory death: comparison of two kidney preservation protocols on graft outcomesClaire Delsuc, Alexandre Faure, Julien Berthiller, et al.Oncotarget|June 2, 2016
Proliferation and ovarian hormone signaling are impaired in normal breast tissues from women with BRCA1 mutations: benefit of a progesterone receptor modulator treatment as a breast cancer preventive strategy in women with inherited BRCA1 mutationsLaudine Communal, Myriam Vilasco, Justine Hugon-Rodin, et al.Cancers|December 10, 2021
Copper-64-Labeled 1C1m-Fc, a New Tool for TEM-1 PET Imaging and Prediction of Lutetium-177-Labeled 1C1m-Fc Therapy Efficacy and SafetyJudith Anna Delage, Silvano Gnesin, John O Prior, et al.Frontiers in Immunology|October 19, 2018
Both Monoclonal and Polyclonal Immunoglobulin Contingents Mediate Complement Activation in Monoclonal Gammopathy Associated-C3 GlomerulopathySophie Chauvet, Lubka T Roumenina, Pierre Aucouturier, et al.Translational Oncology|August 11, 2019
CD63-GPC1-Positive Exosomes Coupled with CA19-9 Offer Good Diagnostic Potential for Resectable Pancreatic Ductal AdenocarcinomaEtienne Buscail, Alexandre Chauvet, Pascaline Quincy, et al.Journal of Gynecology Obstetrics and Human Reproduction|November 6, 2025
Evaluating the applicability of ESGO quality indicators in the surgical management of endometrial cancer: Insights from a Francogyn cohortJerome Lorenzini, Flavie Arbion, Cyril Touboul, et al.Clinical and Translational Radiation Oncology|December 19, 2023
Prospective results for 5-year survival and toxicity of moderately hypofractionated radiotherapy with simultaneous integrated boost (SIB) in (very) high-risk prostate cancerIngrid Masson, Laurène Larriviere, Marc-André Mahé, et al.Clinical Journal of the American Society of Nephrology : CJASN|May 15, 2026
Association of Complement Genetics with Outcomes in IgA NephropathyAnna Duval, Nicolas Maillard, Martin Morin, et al.Pageof 136